INIS
aspirin
25%
asthma
89%
cardiovascular diseases
25%
clinical trials
7%
comparative evaluations
25%
control
6%
coronaviruses
25%
cytokines
8%
data
29%
diseases
100%
drugs
5%
eosinophils
16%
hypothesis
25%
immunotherapy
25%
inflammation
24%
interleukins
53%
management
40%
messenger-rna
25%
methotrexate
25%
monoclonal antibodies
6%
necrosis
25%
nose
9%
patients
69%
psoriasis
25%
reviews
44%
risks
5%
symptoms
10%
therapy
98%
toxicity
25%
united kingdom
25%
vaccines
16%
women
8%
Medicine and Dentistry
Acetylsalicylic Acid
11%
Adverse Event
5%
Allergy
5%
Angioedema
5%
Aspirin Exacerbated Respiratory Disease
25%
Association
25%
Asthma
13%
Chronic Rhinosinusitis
8%
Chronic Urticaria
25%
COVID-19
25%
Development
8%
Diagnosis
25%
Methotrexate
25%
Nasal Polyp
13%
Necrosis
25%
Nonsteroid Antiinflammatory Agent
8%
Pancytopenia
8%
Patient
16%
Psoriasis Vulgaris
25%
RNA Immunization
25%
RNA Vaccine
10%
Skin Manifestation
5%
Subcutaneous Immunotherapy
8%
Sublingual Immunotherapy
8%
Toxicity
25%
Urticaria
5%
Venous Ulcer
25%
Keyphrases
Allergy
5%
Anti-IL-5 Therapy
5%
Aspirin
8%
Aspirin-exacerbated Respiratory Disease
25%
Asthma
13%
Atherosclerotic Cardiovascular Disease (ASCVD)
25%
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
8%
Claims Data
25%
Current Asthma
8%
Cutaneous Psoriasis
6%
Drug Groups
5%
Dutch Hypothesis
5%
Head-to-head Trials
6%
Methotrexate Injection
6%
Methotrexate Toxicity
25%
Nasal Polyps
5%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8%
Phenotype Selection
6%
Plaque Psoriasis
25%
Psoriatic Plaque
6%
Retrospective Review
25%
Selective Approach
8%
Severe Eosinophilic Asthma
6%
Th2 Inflammatory Response
6%
Urticaria Treatment
5%